{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:00:05Z","timestamp":1791644405742,"version":"4.3.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":61,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-53530-3","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:04:35Z","timestamp":1778943875000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pre-treatment of cabozantinib prior to hypofractionated radiotherapy increases immunomodulatory effects and tumor size reduction in a 4T1 breast cancer murine model"],"prefix":"10.1038","volume":"16","author":[{"given":"Fatemeh","family":"Keshavarz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameneh","family":"Kouchaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Soltanshahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Reza","family":"Jaafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad R.","family":"Mafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Shabani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Amir","family":"Jalali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"issue":"7","key":"53530_CR1","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3390\/pharmaceutics15071796","volume":"15","author":"O Obidiro","year":"2023","unstructured":"Obidiro, O., Battogtokh, G. & Akala, E. O. Triple negative breast cancer treatment options and limitations: future outlook. Pharmaceutics. 15 (7), 1796 (2023).","journal-title":"Pharmaceutics"},{"key":"53530_CR2","first-page":"93","volume":"8","author":"J Collignon","year":"2016","unstructured":"Collignon, J., Lousberg, L., Schroeder, H. & Jerusalem, G. Triple-negative breast cancer: treatment challenges and solutions. Breast Cancer (Dove Med. Press). 8, 93\u2013107 (2016).","journal-title":"Breast Cancer (Dove Med. Press)"},{"issue":"10","key":"53530_CR3","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.3390\/cancers12102835","volume":"12","author":"S Cheng","year":"2020","unstructured":"Cheng, S., Cheadle E, J. & Illidge, M. Understanding the effects of radiotherapy on the tumour immune microenvironment to identify potential prognostic and predictive biomarkers of radiotherapy response. Cancers 12 (10), 2835 (2020).","journal-title":"Cancers"},{"issue":"3","key":"53530_CR4","doi-asserted-by":"publisher","first-page":"687","DOI":"10.32604\/or.2024.052133","volume":"33","author":"S Chen","year":"2025","unstructured":"Chen, S. et al. Preventive effects of low-dose radiation and hypofractionated radiation plus anti-programmed cell death protein 1 on lung metastasis in breast cancer. Oncol. Res. 33 (3), 687 (2025).","journal-title":"Oncol. Res."},{"issue":"21","key":"53530_CR5","doi-asserted-by":"publisher","first-page":"5190","DOI":"10.3390\/cancers14215190","volume":"14","author":"S Takanen","year":"2022","unstructured":"Takanen, S., Bottero, M., Nistic\u00f2, P. & Sanguineti, G. A systematic review on the impact of hypofractionated and stereotactic radiotherapy on immune cell subpopulations in cancer patients. Cancers 14 (21), 5190 (2022).","journal-title":"Cancers"},{"issue":"23","key":"53530_CR6","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1097\/CM9.0000000000002535","volume":"136","author":"Z Zhang","year":"2023","unstructured":"Zhang, Z. et al. Effects of radiation therapy on tumor microenvironment: an updated review. Chin. Med. J. 136 (23), 2802\u20132811 (2023).","journal-title":"Chin. Med. J."},{"key":"53530_CR7","doi-asserted-by":"publisher","first-page":"1074477","DOI":"10.3389\/fimmu.2022.1074477","volume":"13","author":"S Zhu","year":"2022","unstructured":"Zhu, S., Wang, Y., Tang, J. & Cao, M. Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment. Front. Immunol. 13, 1074477 (2022).","journal-title":"Front. Immunol."},{"issue":"4","key":"53530_CR8","first-page":"209","volume":"15","author":"M Alimohammadi","year":"2023","unstructured":"Alimohammadi, M. et al. Radiotherapy Combination: Insight from Tumor Immune Microenvironment (TIME). Avicenna J. Med. Biotechnol. 15 (4), 209 (2023).","journal-title":"Avicenna J. Med. Biotechnol."},{"issue":"24","key":"53530_CR9","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.21037\/atm-22-6049","volume":"10","author":"N-H Wang","year":"2022","unstructured":"Wang, N-H. et al. Radiation-induced PD-L1 expression in tumor and its microenvironment facilitates cancer-immune escape: a narrative review. Ann. Trans. Med. 10 (24), 1406 (2022).","journal-title":"Annals Translational Med."},{"issue":"2","key":"53530_CR10","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.3892\/ol.2017.6305","volume":"14","author":"K Gonda","year":"2017","unstructured":"Gonda, K. et al. Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer. Oncol. Lett. 14 (2), 1766\u20131774 (2017).","journal-title":"Oncol. Lett."},{"key":"53530_CR11","doi-asserted-by":"publisher","first-page":"1199273","DOI":"10.3389\/fimmu.2023.1199273","volume":"14","author":"H Liu","year":"2023","unstructured":"Liu, H., Wang, Z., Zhou, Y. & Yang, Y. MDSCs in breast cancer: an important enabler of tumor progression and an emerging therapeutic target. Front. Immunol. 14, 1199273 (2023).","journal-title":"Front. Immunol."},{"issue":"8","key":"53530_CR12","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.3390\/cells9081785","volume":"9","author":"YJ Cha","year":"2020","unstructured":"Cha, Y. J. & Koo, J. S. Role of tumor-associated myeloid cells in breast cancer. Cells 9 (8), 1785 (2020).","journal-title":"Cells"},{"issue":"6","key":"53530_CR13","doi-asserted-by":"publisher","first-page":"5208","DOI":"10.3390\/ijms24065208","volume":"24","author":"ML S\u00e1nchez-Le\u00f3n","year":"2023","unstructured":"S\u00e1nchez-Le\u00f3n, M. L. et al. Defining the emergence of new immunotherapy approaches in breast cancer: role of myeloid-derived suppressor cells. Int. J. Mol. Sci. 24 (6), 5208 (2023).","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"53530_CR14","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/phar.2076","volume":"38","author":"JN Markowitz","year":"2018","unstructured":"Markowitz, J. N. & Fancher, K. M. Cabozantinib: a multitargeted oral tyrosine kinase inhibitor. Pharmacotherapy: J. Hum. Pharmacol. Drug Therapy. 38 (3), 357\u2013369 (2018).","journal-title":"Pharmacotherapy: J. Hum. Pharmacol. Drug Therapy"},{"issue":"31","key":"53530_CR15","doi-asserted-by":"publisher","first-page":"2302046","DOI":"10.1002\/adhm.202302046","volume":"12","author":"Z Gu","year":"2023","unstructured":"Gu, Z. et al. Dual-targeting nanoliposome improves proinflammatory immunomodulation of the tumor microenvironment. Adv. Healthc. Mater. 12 (31), 2302046 (2023).","journal-title":"Adv. Healthc. Mater."},{"key":"53530_CR16","doi-asserted-by":"publisher","first-page":"S483","DOI":"10.1016\/j.annonc.2022.05.108","volume":"33","author":"D-L Ou","year":"2022","unstructured":"Ou, D-L. et al. MO5-2 Cabozantinib may enhance efficacy of anti-PD-1 therapy in hepatocellular carcinoma through suppression of MDSCs. Ann. Oncol. 33, S483 (2022).","journal-title":"Ann. Oncol."},{"key":"53530_CR17","doi-asserted-by":"publisher","first-page":"viii312","DOI":"10.1093\/annonc\/mdy283.091","volume":"29","author":"E Verzoni","year":"2018","unstructured":"Verzoni, E. et al. Potent natural killer (NK) and myeloid blood cell remodeling by cabozantinib (Cabo) in pre-treated metastatic renal cell carcinoma (mRCC) patients (pts). Ann. Oncol. 29, viii312 (2018).","journal-title":"Ann. Oncol."},{"key":"53530_CR18","doi-asserted-by":"publisher","first-page":"109470","DOI":"10.1016\/j.intimp.2022.109470","volume":"113","author":"VK Bakhtiarvand","year":"2022","unstructured":"Bakhtiarvand, V. K. et al. Myeloid-derived suppressor cells (MDSCs) depletion by cabozantinib improves the efficacy of anti-HER2 antibody-based immunotherapy in a 4T1-HER2 murine breast cancer model. Int. Immunopharmacol. 113, 109470 (2022).","journal-title":"Int. Immunopharmacol."},{"issue":"8","key":"53530_CR19","doi-asserted-by":"publisher","first-page":"e0273547","DOI":"10.1371\/journal.pone.0273547","volume":"17","author":"E Rostami","year":"2022","unstructured":"Rostami, E. et al. Combining ablative radiotherapy and anti CD47 monoclonal antibody improves infiltration of immune cells in tumor microenvironments. Plos one. 17 (8), e0273547 (2022).","journal-title":"Plos one"},{"key":"53530_CR20","doi-asserted-by":"publisher","first-page":"117906441876163","DOI":"10.1177\/1179064418761639","volume":"11","author":"KM Arnold","year":"2018","unstructured":"Arnold, K. M. et al. The impact of radiation on the tumor microenvironment: effect of dose and fractionation schedules. Cancer growth metastasis. 11, 1179064418761639 (2018).","journal-title":"Cancer growth metastasis"},{"issue":"2","key":"53530_CR21","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ijrobp.2023.09.014","volume":"118","author":"H Kim","year":"2024","unstructured":"Kim, H. et al. Five-day spacing of two fractionated ablative radiotherapies enhances antitumor immunity. Int. J. Radiation Oncology* Biology* Phys. 118 (2), 498\u2013511 (2024).","journal-title":"Int. J. Radiation Oncology* Biology* Phys."},{"issue":"1","key":"53530_CR22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ijrobp.2018.01.094","volume":"101","author":"X Zhang","year":"2018","unstructured":"Zhang, X. & Niedermann, G. Abscopal effects with hypofractionated schedules extending into the effector phase of the tumor-specific T-cell response. Int. J. Radiation Oncology* Biology* Phys. 101 (1), 63\u201373 (2018).","journal-title":"Int. J. Radiation Oncology* Biology* Phys."},{"key":"53530_CR23","doi-asserted-by":"publisher","first-page":"788182","DOI":"10.3389\/fonc.2021.788182","volume":"11","author":"N Reppingen","year":"2021","unstructured":"Reppingen, N., Helm, A., Doleschal, L., Durante, M. & Fournier, C. A combination of cabozantinib and radiation does not lead to an improved growth control of tumors in a preclinical 4T1 breast cancer model. Front. Oncol. 11, 788182 (2021).","journal-title":"Front. Oncol."},{"issue":"38","key":"53530_CR24","doi-asserted-by":"publisher","first-page":"23721","DOI":"10.1073\/pnas.2001933117","volume":"117","author":"J Chow","year":"2020","unstructured":"Chow, J. et al. Radiation induces dynamic changes to the T cell repertoire in renal cell carcinoma patients. Proc. Natl. Acad. Sci. U S A. 117 (38), 23721\u201323729 (2020).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"1","key":"53530_CR25","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41698-023-00358-z","volume":"7","author":"E Gkika","year":"2023","unstructured":"Gkika, E. et al. Systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer. NPJ Precision Oncol. 7 (1), 24 (2023).","journal-title":"NPJ Precision Oncol."},{"key":"53530_CR26","doi-asserted-by":"publisher","first-page":"648652","DOI":"10.3389\/fimmu.2021.648652","volume":"12","author":"Q Wang","year":"2021","unstructured":"Wang, Q. et al. Changes in T lymphocyte subsets in different tumors before and after radiotherapy: a meta-analysis. Front. Immunol. 12, 648652 (2021).","journal-title":"Front. Immunol."},{"key":"53530_CR27","doi-asserted-by":"publisher","first-page":"100808","DOI":"10.1016\/j.neo.2022.100808","volume":"31","author":"MJ Gough","year":"2022","unstructured":"Gough, M. J. & Crittenden, M. R. The paradox of radiation and T cells in tumors. Neoplasia 31, 100808 (2022).","journal-title":"Neoplasia"},{"issue":"2","key":"53530_CR28","doi-asserted-by":"publisher","first-page":"e1267095","DOI":"10.1080\/2162402X.2016.1267095","volume":"6","author":"H van Meir","year":"2017","unstructured":"van Meir, H. et al. Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients. Oncoimmunology 6 (2), e1267095 (2017).","journal-title":"Oncoimmunology"},{"key":"53530_CR29","doi-asserted-by":"publisher","first-page":"108737","DOI":"10.1016\/j.intimp.2022.108737","volume":"108","author":"H Ghaffari-Nazari","year":"2022","unstructured":"Ghaffari-Nazari, H. et al. Radiation dose and schedule influence the abscopal effect in a bilateral murine CT26 tumor model. Int. Immunopharmacol. 108, 108737 (2022).","journal-title":"Int. Immunopharmacol."},{"issue":"24","key":"53530_CR30","doi-asserted-by":"publisher","first-page":"5038","DOI":"10.1158\/1078-0432.CCR-23-1142","volume":"29","author":"M Haigentz Jr","year":"2023","unstructured":"Haigentz, M. Jr. et al. Phase I Trial of the multi-kinase inhibitor cabozantinib, a CYP3A4 substrate, plus CYP3A4-interacting antiretroviral therapy in people living with HIV and cancer (AMC-087). Clin. Cancer Res. 29 (24), 5038\u20135046 (2023).","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"53530_CR31","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1038\/s41591-024-03086-4","volume":"30","author":"H Ebrahimi","year":"2024","unstructured":"Ebrahimi, H. et al. Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat. Med. 30 (9), 2576\u20132585 (2024).","journal-title":"Nat. Med."},{"issue":"11","key":"53530_CR32","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/intbio\/zyab018","volume":"13","author":"KY Park","year":"2021","unstructured":"Park, K. Y. et al. Immune cell mediated cabozantinib resistance for patients with renal cell carcinoma. Integr. Biology. 13 (11), 259\u2013268 (2021).","journal-title":"Integr. Biology"},{"key":"53530_CR33","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12967-014-0294-y","volume":"12","author":"AR Kwilas","year":"2014","unstructured":"Kwilas, A. R., Ardiani, A., Donahue, R. N., Aftab, D. T. & Hodge, J. W. Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine. J. Transl Med. 12, 294 (2014).","journal-title":"J. Transl Med."},{"issue":"11","key":"53530_CR34","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1158\/1078-0432.CCR-21-2517","volume":"28","author":"R Esteban-Fabr\u00f3","year":"2022","unstructured":"Esteban-Fabr\u00f3, R. et al. Cabozantinib enhances anti-PD1 activity and elicits a neutrophil-based immune response in hepatocellular carcinoma. Clin. Cancer Res. 28 (11), 2449\u20132460 (2022).","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"53530_CR35","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1158\/1535-7163.MCT-18-1399","volume":"18","author":"P Bergerot","year":"2019","unstructured":"Bergerot, P., Lamb, P., Wang, E. & Pal, S. K. Cabozantinib in combination with immunotherapy for advanced renal cell carcinoma and urothelial carcinoma: rationale and clinical evidence. Mol. Cancer Ther. 18 (12), 2185\u20132193 (2019).","journal-title":"Mol. Cancer Ther."},{"issue":"50","key":"53530_CR36","doi-asserted-by":"publisher","first-page":"87891","DOI":"10.18632\/oncotarget.21248","volume":"8","author":"M Tripathi","year":"2017","unstructured":"Tripathi, M. et al. Modulation of cabozantinib efficacy by the prostate tumor microenvironment. Oncotarget 8 (50), 87891 (2017).","journal-title":"Oncotarget"},{"key":"53530_CR37","doi-asserted-by":"publisher","first-page":"115009","DOI":"10.1016\/j.intimp.2025.115009","volume":"161","author":"J Xu","year":"2025","unstructured":"Xu, J. et al. Tumor-associated macrophages in radiotherapy: mechanisms of polarization, immune regulation and therapeutic strategies. Int. Immunopharmacol. 161, 115009 (2025).","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"53530_CR38","doi-asserted-by":"publisher","first-page":"e000667","DOI":"10.1136\/jitc-2020-000667","volume":"8","author":"V Stary","year":"2020","unstructured":"Stary, V. et al. Short-course radiotherapy promotes pro-inflammatory macrophages via extracellular vesicles in human rectal cancer. J. Immunother. Cancer. 8 (2), e000667 (2020).","journal-title":"J. Immunother. Cancer"},{"issue":"11","key":"53530_CR39","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1111\/jcmm.12109","volume":"17","author":"F Pantano","year":"2013","unstructured":"Pantano, F. et al. The role of macrophages polarization in predicting prognosis of radically resected gastric cancer patients. J. Cell. Mol. Med. 17 (11), 1415\u20131421 (2013).","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"53530_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12865-018-0241-4","volume":"19","author":"J Jackute","year":"2018","unstructured":"Jackute, J. et al. Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancer. BMC Immunol. 19 (1), 3 (2018).","journal-title":"BMC Immunol."},{"issue":"1","key":"53530_CR41","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s12935-021-02089-2","volume":"21","author":"J Liu","year":"2021","unstructured":"Liu, J., Geng, X., Hou, J. & Wu, G. New insights into M1\/M2 macrophages: key modulators in cancer progression. Cancer Cell. Int. 21 (1), 389 (2021).","journal-title":"Cancer Cell. Int."},{"issue":"1","key":"53530_CR42","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ijrobp.2023.11.050","volume":"119","author":"KMB Bergerud","year":"2024","unstructured":"Bergerud, K. M. B. et al. Radiation therapy and myeloid-derived suppressor cells: breaking down their cancerous partnership. Int. J. Radiat. Oncol. Biol. Phys. 119 (1), 42\u201355 (2024).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"7","key":"53530_CR43","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1016\/j.ymthe.2023.04.008","volume":"31","author":"B Zhang","year":"2023","unstructured":"Zhang, B. et al. Optimized CAR-T therapy based on spatiotemporal changes and chemotactic mechanisms of MDSCs induced by hypofractionated radiotherapy. Mol. Ther. 31 (7), 2105\u20132119 (2023).","journal-title":"Mol. Ther."},{"issue":"9","key":"53530_CR44","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1158\/1078-0432.CCR-23-3206","volume":"30","author":"Y Hou","year":"2024","unstructured":"Hou, Y. et al. Radiotherapy enhances Metastasis through Immune suppression by inducing PD-L1 and MDSC in Distal sites. Clin. Cancer Res. 30 (9), 1945\u20131958 (2024).","journal-title":"Clin. Cancer Res."},{"key":"53530_CR45","doi-asserted-by":"publisher","first-page":"967480","DOI":"10.3389\/fruro.2022.967480","volume":"2","author":"Y Kohada","year":"2022","unstructured":"Kohada, Y. et al. Circulating PMN-MDSC level positively correlates with a poor prognosis in patients with metastatic hormone-sensitive prostate cancer. Front. Urol. 2, 967480 (2022).","journal-title":"Front. Urol."},{"issue":"2","key":"53530_CR46","doi-asserted-by":"publisher","first-page":"e001223","DOI":"10.1136\/jitc-2020-001223","volume":"8","author":"L Cassetta","year":"2020","unstructured":"Cassetta, L. et al. Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation. J. Immunother. Cancer. 8 (2), e001223 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"53530_CR47","doi-asserted-by":"publisher","first-page":"104280","DOI":"10.1016\/j.cellimm.2020.104280","volume":"361","author":"SG Kalathil","year":"2021","unstructured":"Kalathil, S. G. & Thanavala, Y. Importance of myeloid derived suppressor cells in cancer from a biomarker perspective. Cell. Immunol. 361, 104280 (2021).","journal-title":"Cell. Immunol."},{"issue":"1","key":"53530_CR48","doi-asserted-by":"publisher","first-page":"19740","DOI":"10.1038\/srep19740","volume":"6","author":"C-T Wu","year":"2016","unstructured":"Wu, C-T., Chen, W-C., Chang, Y-H., Lin, W-Y. & Chen, M-F. The role of PD-L1 in the radiation response and clinical outcome for bladder cancer. Sci. Rep. 6 (1), 19740 (2016).","journal-title":"Sci. Rep."},{"issue":"7","key":"53530_CR49","doi-asserted-by":"publisher","first-page":"e1442168","DOI":"10.1080\/2162402X.2018.1442168","volume":"7","author":"KR Patel","year":"2018","unstructured":"Patel, K. R. et al. Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma. Oncoimmunology 7 (7), e1442168 (2018).","journal-title":"Oncoimmunology"},{"issue":"3","key":"53530_CR50","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","volume":"37","author":"V Kumar","year":"2016","unstructured":"Kumar, V., Patel, S., Tcyganov, E. & Gabrilovich, D. I. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 37 (3), 208\u2013220 (2016).","journal-title":"Trends Immunol."},{"issue":"5","key":"53530_CR51","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.31557\/APJCP.2024.25.5.1559","volume":"25","author":"R Rafli","year":"2024","unstructured":"Rafli, R., Harahap, W. A., Gondhowiardjo, S. & Ekaputra, A. Investigating radiotherapy effects on PD-L1 expression in Circulating tumor cells: an exploratory study. Asian Pac. J. cancer prevention: APJCP. 25 (5), 1559 (2024).","journal-title":"Asian Pac. J. cancer prevention: APJCP"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53530-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53530-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53530-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T19:02:17Z","timestamp":1784228537000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53530-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,16]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["53530"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-53530-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,16]]},"assertion":[{"value":"22 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors approved this manuscript. No competing interests declared.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Shahid Beheshti University of Medical Sciences under the Number IR.SBMU.AEC.1403.030.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"22312"}}